InvestorsObserver
×
News Home

Is it Time to Dump Zai Lab Ltd - ADR (ZLAB) Stock After it Is Up 8.51% in a Week?

Monday, March 27, 2023 02:46 PM | InvestorsObserver Analysts

Mentioned in this article

Is it Time to Dump Zai Lab Ltd - ADR (ZLAB) Stock After it Is Up 8.51% in a Week?

Zai Lab Ltd - ADR (ZLAB) stock has risen 8.51% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,neutral
Zai Lab Ltd - ADR has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on ZLAB!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With ZLAB Stock Today?

Zai Lab Ltd - ADR (ZLAB) stock is trading at $32.78 as of 2:43 PM on Monday, Mar 27, a gain of $1.08, or 3.39% from the previous closing price of $31.70. The stock has traded between $31.72 and $32.78 so far today. Volume today is low. So far 147,140 shares have traded compared to average volume of 669,891 shares.

More About Zai Lab Ltd - ADR

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatment across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC. Click Here to get the full Stock Report for Zai Lab Ltd - ADR stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App